DURECT Corp. (DRRX) Stock Rebounds in Aftermarket, Here’s why?
DURECT Corp. (DRRX) is a leading biotherapeutics company transforming acute organ injury and chronic liver diseases treatment by using its epigenetic regulator program. The company’s lead pipeline candidate Larsucosterol or DUR-928 treats hypermethylation in alcohol-associated hepatitis patients. Additionally, POSIMIR is a non-opioid analgesic that uses SABER platform technology. The price of DRRX stock during the […]
